Akkermansia muciniphila is a gram-negative bacterium that lives in the mucus layer coating your intestinal wall. In one study of human samples it was found at more than 1% of faecal cells, but abundance varies widely between people, and it was undetectable in 45.3% of 786 older Japanese adults [7][8][9]. Its unusual position, feeding directly on the mucin glycoproteins that form intestinal mucus, has drawn considerable scientific attention, and low levels of this organism turn up repeatedly in people with obesity, type 2 diabetes, and metabolic liver conditions.
Research into Akkermansia is still maturing. A meaningful portion of the mechanistic evidence comes from animal studies or small human trials, and associations between Akkermansia abundance and health outcomes do not by themselves establish cause and effect. This article explains what the bacterium does in the gut, the proposed pathways through which it may influence metabolism and barrier function, and what current evidence, including studies on dietary polyphenols, says about maintaining its populations. Nothing here constitutes medical advice.
Key Takeaways
- Akkermansia muciniphila inhabits the intestinal mucus layer and comprises more than 1% of a healthy gut microbiome, where it is proposed to strengthen barrier integrity and influence metabolic signaling.
- Lower Akkermansia abundance has been reported in some studies of obesity, type 2 diabetes and fatty liver disease, but findings are inconsistent across studies, and EFSA noted that these observational studies lack a longitudinal design and may reflect reverse causation [10][11][12][13][14].
- Pomegranate evidence is mixed: in culture, pomegranate extract inhibited Akkermansia growth at the concentrations tested, while in people given pomegranate extract a higher proportion of Akkermansia went with being a urolithin A producer, an association only [1][15].
- In a shotgun-sequencing study of adults with prediabetes and insulin resistance, A. muciniphila was depleted in the lean subset compared with a metabolically healthy reference group, which is an abundance association only [2].
- Akkermansia supplements are not FDA-approved to treat any condition; evidence in humans is early, and immunocompromised individuals should consult a physician before use.
What Is Akkermansia muciniphila and Where Does It Live?
Akkermansia muciniphila belongs to the phylum Verrucomicrobia, a lineage uncommon in nature but disproportionately well represented in the human intestine. First isolated and characterized in 2004, it colonizes the mucus layer that sits between the epithelial cell surface and the gut lumen: a location that places it at a critical interface between the microbial world and the body’s own tissue.
Akkermansia was detected in few infants but in nearly all adults and older people in one study
Whether Akkermansia is present depends on age and on the population studied.
Stool qPCR in 249 people from infants to elderly, as reviewed by EFSA. Different people at each age, an association study with no supplementation. Source: EFSA 2021; Naito et al., Microorganisms 2026
Data table
| Item | Value |
|---|---|
| 1 month old | 16% detected |
| 6 months old | 72% detected |
| 12 months old | 90% detected |
| Adults | 100% detected |
| Elderly | 96% detected |
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
Unlike the majority of colonic bacteria that depend on dietary fiber as their primary carbon source, Akkermansia derives energy by breaking down mucin, the glycoprotein scaffold of intestinal mucus. This relationship is not simply destructive. Current thinking holds that controlled mucin degradation stimulates the host epithelium to upregulate mucus production, effectively keeping the layer thick and continuously renewed. The bacterium’s ecological niche therefore depends on, and may reinforce, the very structure it inhabits.
Proposed Roles in Gut Barrier Integrity and Metabolic Signaling
Several mechanistic pathways have been proposed to explain why higher Akkermansia abundance associates with better metabolic outcomes in observational studies. One involves Amuc_1100, an outer membrane protein that is thought to interact with intestinal toll-like receptor 2 (TLR2), a signaling pathway linked to tight-junction reinforcement. Tight junctions are the protein complexes sealing the spaces between epithelial cells; their disruption, sometimes called increased intestinal permeability, is associated with low-grade systemic inflammation and metabolic dysregulation.
Research note: In 7 healthy people followed over 52 time points, A. muciniphila detection rates were 56.9% by 16S rRNA sequencing and 33.3% by whole-genome sequencing, with large swings in relative abundance [31].
A second proposed mechanism involves short-chain fatty acids and other metabolites produced during mucin fermentation, which may supply energy to the colonocytes lining the gut wall. A third line of evidence comes from trials of pasteurized Akkermansia: a 2019 pilot in overweight or obese insulin-resistant adults reported improved insulin sensitivity versus placebo, while a larger 142-adult trial missed its primary endpoint. GLP-1 effects have been shown only in cells and mice [16][17][18][19]. These findings are preliminary, and Akkermansia supplements are not approved by the FDA to treat or prevent any disease.
Akkermansia-associated microbial communities are also connected to liver health through what researchers call the gut-microbiota-liver axis. Studies examining urolithin A, a metabolite produced when gut bacteria process ellagitannins from foods like pomegranate, have found it to have effects on this axis in preclinical models of chronic liver disease [3]. Separately, a mouse study of obacunone, a dietary limonoid, found that it raised the abundance of the genus Akkermansia alongside lower liver fat and injury markers, but it did not test whether Akkermansia drove the liver effect [4].
Why Akkermansia Levels Decline
Akkermansia abundance is not fixed throughout life. It shifts in response to diet, medications, aging, and underlying health status, and several categories of decline are reasonably well characterized. Antibiotic effects are mixed: antibiotic use was associated with low Akkermansia in cancer patients, but oral vancomycin was followed by an increase in A. muciniphila in a small inpatient study of 27 volunteers. Recovery times for Akkermansia specifically have not been established in these studies [20][21][22].
Diet quality is an equally important driver. In mice, a high-fat diet thinned the colonic mucus layer and depleted Akkermansia, and a review links Western diets and ultra-processed foods to depletion of taxa such as Akkermansia. In 786 older Japanese adults, a noodle-based dietary pattern was associated with lower odds of detecting Akkermansia. In adults with prediabetes and insulin resistance, A. muciniphila was depleted in the lean subset compared with a metabolically healthy reference group [23][24][9][2].
Age is a third factor, but the data are mixed: young adults had less Akkermansia by qPCR than elderly people in one study, Chinese centenarians had less than younger elderly people, and long-lived cohorts in other studies were enriched in Akkermansia. Obesity, type 2 diabetes and fatty liver disease have been associated with lower Akkermansia levels in cross-sectional data, though the directional relationship, whether the microbial decline precedes or follows metabolic dysfunction, has not been established in humans. Not every condition shows lower levels: Akkermansia was higher in people with Parkinson’s disease (a meta-analysis of six datasets) and in multiple sclerosis [25][26][27][10][11][12][14][28][29].
Polyphenols, Ellagitannins, and Akkermansia: A Dietary Connection
Among dietary interventions studied for their effect on Akkermansia, pomegranate ellagitannins are a commonly cited example, but the evidence is mixed. In culture, ellagic acid at 10 Ī¼M did not change A. muciniphila growth and pomegranate extract at 0.18 and 0.28 mg/ml significantly inhibited it, while in people given pomegranate extract a higher proportion of Akkermansia went with being a urolithin A producer, an association only. A review of pomegranate and gut microbiota notes that A. muciniphila has been described as one of the bacteria that biotransform pomegranate compounds into urolithin, which conflicts with a culture study concluding that other bacteria form urolithin A [1][15][5].
Ellagic acid, the precursor released when ellagitannins are hydrolyzed in the gut, has also been studied in the context of aging and microbiome composition. In d-galactose-aged rats, ellagic acid altered gut microbiota structure and enhanced urolithin A production, and high urolithin A-producing rats had Akkermansia abundance 139.21% greater than the model group, while antibiotics almost offset the anti-aging effect. This is a rat result and does not show that polyphenol-rich foods maintain Akkermansia in people [6].
The practical implication is that a diet regularly including pomegranate, walnuts, berries, and other ellagitannin-containing foods may support Akkermansia-favorable microbial communities. Individual responses vary considerably based on existing microbiome composition, and no single food or supplement is established to reliably raise Akkermansia levels in all people.
Urolithin A as a Marker of Akkermansia-Supporting Microbial Activity
Urolithin A is formed when gut bacteria convert dietary ellagitannins, and the capacity to complete this conversion varies between individuals. In people given pomegranate extract, urolithin A formation was associated with a high proportion of A. muciniphila in stool, but the authors concluded that A. muciniphila is not itself the urolithin A producer, so urolithin A output is not a direct readout of Akkermansia activity [1][15][5].
In adults with prediabetes and insulin resistance, A. muciniphila was depleted in the lean subset compared with a metabolically healthy reference group in one shotgun-sequencing study, which is an abundance association only. Urolithin A has also been studied in mice with chronic alcohol-related liver disease, where it enriched several bacteria including Akkermansia muciniphila and their metabolite propionic acid, but Akkermansia was one of several measured changes, not the sole mediator [2][3].
Supporting Akkermansia Through Lifestyle and Diet: What Is Currently Known
No single dietary strategy has been shown to raise Akkermansia reliably. Pomegranate evidence is mixed, and the ellagic acid result comes from rats. A systematic review of dietary trials reported higher abundance with calorie restriction and with supplements including pomegranate extract and inulin, but only five of 29 trials examined Akkermansia alone and the review says the evidence is not clear [1][6][30].
Beyond diet, avoiding unnecessary antibiotic use, maintaining adequate sleep, managing chronic psychological stress, and engaging in regular physical activity are all associated with healthier overall microbiome composition. Commercially available pasteurized Akkermansia supplements have been assessed in some human trials and have shown a generally acceptable safety profile in healthy and overweight populations, though long-term, large-scale data are limited. Live probiotic formulations carry additional considerations discussed in the caution below. A polyphenol-rich, diverse-food pattern is a reasonable general approach, but trials have not shown that it raises Akkermansia enough to change health outcomes [30].
š Where to Buy Akkermansia muciniphila
- Pendulum Akkermansia
delayed-release capsules, 100M AFU: Live A. muciniphila strain (WB-STR-0001); single-strain with chicory inulin, third-party tested. - Codeage Akkermansia Muciniphila
capsules, 100M AFU, 90 ct: Lower-cost Akkermansia plus chicory inulin synbiotic; 3-month supply, gluten-free. - Double Wood Akkermansia Probiotic + Postbiotic
capsules, per label: Budget Akkermansia option marketed around GLP-1 and postbiotic support.
As an Amazon Associate we earn from qualifying purchases. Akkermansia is a live, oxygen-sensitive strain: choose a delayed-release, third-party-tested product with a stated live AFU count.
A Note on the Evidence
The human evidence base for Akkermansia muciniphila is still limited primarily to small-scale trials and observational data; a significant proportion of mechanistic findings come from animal models, and causal conclusions cannot yet be drawn. Live Akkermansia probiotic formulations are not appropriate for immunocompromised individuals, those receiving immunosuppressive medications, or anyone with active inflammatory bowel disease without prior consultation with a qualified healthcare provider.
Frequently Asked Questions
What does Akkermansia muciniphila actually do in the gut?
It degrades mucin glycoproteins in the intestinal mucus layer for energy while stimulating the host to continuously renew that layer. It is also proposed to reinforce tight junctions between epithelial cells via its outer membrane protein Amuc_1100. GLP-1 effects have been shown in cells and mice, not in people, and human insulin sensitivity results are mixed: a 2019 pilot was positive for the pasteurized form, while a larger 142-adult trial missed its primary endpoint [18][19][16][17].
Why would someone have low Akkermansia levels?
Factors linked to lower Akkermansia in studies include diets high in ultra-processed foods, obesity and type 2 diabetes. These are associations, antibiotic effects are mixed (oral vancomycin raised A. muciniphila in one small study), and findings on age are inconsistent. In a shotgun-sequencing study, A. muciniphila was depleted in the lean subset of adults with prediabetes and insulin resistance [24][10][11][21][25][2].
Can eating pomegranate raise Akkermansia levels?
Evidence is mixed. In culture, pomegranate extract inhibited Akkermansia growth at the concentrations tested, while in people given pomegranate extract a higher proportion of Akkermansia went with being a urolithin A producer, an association only. Individual responses vary based on pre-existing microbiome composition and overall diet quality [1].
What is urolithin A and how does it connect to Akkermansia?
Urolithin A is a metabolite formed when gut bacteria convert ellagitannins from foods like pomegranate. In people given pomegranate extract, urolithin A formation was associated with a high proportion of A. muciniphila in stool, but the authors concluded A. muciniphila is not itself the producer. Urolithin A has shown effects on the gut-microbiota-liver axis in mice with chronic alcohol-related liver disease [1][3].
Is aging an important factor in Akkermansia decline?
The data are mixed. Young adults had less Akkermansia by qPCR than elderly people in one study, Chinese centenarians had less than younger elderly people, and long-lived cohorts in other studies were enriched in Akkermansia. In d-galactose-aged rats, ellagic acid altered gut microbiota and urolithin A-producing capacity, but that is a rat result [25][26][27][6].
Are Akkermansia supplements safe to take?
Pasteurized Akkermansia preparations have been assessed in small human studies with a generally acceptable safety profile in healthy and overweight adults. However, live probiotic formulations may carry risk for immunocompromised individuals, those on immunosuppressive therapy, or people with active inflammatory bowel disease. Akkermansia supplements are not FDA-approved to treat, cure, or prevent any disease, and a healthcare provider should be consulted before starting any probiotic supplement.
References
- Henning SM et al. Pomegranate ellagitannins stimulate the growth of Akkermansia muciniphila inĀ vivo. Anaerobe (2017). PMID 27940244
- Zhang X et al. Functional Deficits in Gut Microbiome of Young and Middle-Aged Adults with Prediabetes Apparent in Metabolizing Bioactive (Poly)phenols. Nutrients (2020). PMID 33238618
- Zhang H et al. MUP1 mediates urolithin A alleviation of chronic alcohol-related liver disease via gut-microbiota-liver axis. Gut microbes (2024). PMID 38889450
- Wang X et al. Obacunone ameliorates high-fat diet-induced MAFLD by regulating the PPARĪ³-FABP1/CD36 axis and the gut-liver crosstalk. Phytomedicine : international journal of phytotherapy and phytopharmacology (2025). PMID 40850071
- Yin Y et al. Crosstalk between dietary pomegranate and gut microbiota: evidence of health benefits. Critical reviews in food science and nutrition (2024). PMID 37335106
- Xian W et al. Ameliorative Effect of Ellagic Acid on Aging in Rats with the Potential Mechanism Relying on the Gut Microbiota and Urolithin A-Producing Ability. Journal of agricultural and food chemistry (2023). PMID 37132992
- Derrien M et al. The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract. Applied and environmental microbiology (2008). PMID 18083887
- van Passel MW et al. The genome of Akkermansia muciniphila, a dedicated intestinal mucin degrader, and its use in exploring intestinal metagenomes. PloS one (2011). PMID 21390229
- Naito Y et al. Low Prevalence and Abundance of Akkermansia in Older Japanese Adults: Inverse Association with a Noodle-Based Dietary Pattern but Not with Physical Function. Microorganisms (2026). PMID 42655074
- Maria Carlota Dao et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut (2015). PMID 26100928
- ChingāTang Shih et al. Akkermansia muciniphila is Negatively Correlated with Hemoglobin A1c in Refractory Diabetes. Microorganisms (2020). PMID 32899513
- Lee NY et al. Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis. Clinical and molecular hepatology (2021). PMID 33317254
- Letchumanan G et al. Gut Microbiota Composition in Prediabetes and Newly Diagnosed Type 2 Diabetes: A Systematic Review of Observational Studies. Frontiers in cellular and infection microbiology (2022). PMID 36046745
- European Food Safety Authority (NDA Panel) Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. European Food Safety Authority (NDA Panel) (2021). source
- Li Z et al. Pomegranate extract induces ellagitannin metabolite formation and changes stool microbiota in healthy volunteers. Food & function (2015). PMID 26189645
- Liu Y et al. Pasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities. Frontiers in pharmacology (2026). PMID 42846334
- Suenaert P et al. Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels. Gut microbes (2026). PMID 42343233
- Wenxuan Di et al. Heterologous expression of P9 from Akkermansia muciniphila increases the GLP-1 secretion of intestinal L cells. World Journal of Microbiology and Biotechnology (2024). PMID 38727988
- Li Y et al. Peptide LKLKLL is a more effective component of Akkermansia muciniphila which regulate glucolipid metabolism through GLP-1/GIP dual modulation. Gut microbes (2026). PMID 42473065
- Vancheswaran Gopalakrishnan et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (2017). PMID 29097493
- Basolo A et al. Effects of underfeeding and oral vancomycin on gut microbiome and nutrient absorption in humans. Nature medicine (2020). PMID 32235930
- Ouyang J et al. The Bacterium Akkermansia muciniphila: A Sentinel for Gut Permeability and Its Relevance to HIV-Related Inflammation. Frontiers in immunology (2020). PMID 32328074
- Liang X et al. Dietary fat alters goblet cell function and microbial bile acid metabolism to promote intestinal lipid absorption in mice. Nature microbiology (2026). PMID 42271159
- Khial Y et al. Dietary patterns, gut microbiota, and gastrointestinal disorders: mechanistic insights into irritable bowel syndrome and inflammatory bowel disease. Reviews on environmental health (2026). PMID 42448648
- Elena Biagi et al. Through Ageing, and Beyond: Gut Microbiota and Inflammatory Status in Seniors and Centenarians. PLoS ONE (2010). PMID 20498852
- Wang Fang et al. Gut Microbiota Community and Its Assembly Associated with Age and Diet in Chinese Centenarians. Journal of Microbiology and Biotechnology (2015). PMID 25839332
- Chen S et al. Consistent signatures in the human gut microbiome of longevous populations. Gut microbes (2024). PMID 39197040
- Nishiwaki H et al. Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease. NPJ Parkinson's disease (2024). PMID 38773112
- Wenhui Lei et al. Akkermansia muciniphila in neuropsychiatric disorders: friend or foe?. Frontiers in Cellular and Infection Microbiology (2023). PMID 37492530
- Sanne Verhoog et al. Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review. Nutrients (2019). PMID 31336737
- Han N et al. Strain-level dynamics of Akkermansia muciniphila in the human gut microbiota. AMB Express (2025). PMID 41364398
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
